CEACAM5 and neoplasm: This trial was designed with two cohorts based on CEACAM5 expression levels by immunochemistry ≥2+ in moderate expressors (intensity between ≥1% to <50% of tumor cell population) and high expressors (≥50% of the tumor cell population).